Abstract
We examined the influence of adenovirus-mediated wild-type p16INK4a (Ad/p16) expression on the radiation sensitivity of NSCLC cell lines, all of which lacked constitutive p16INK4a but each of which varied in p53 status: A549 (−p16INK4a/+pRb/wt-p53), H322 (−p16INK4a/+pRb/mt-p53), and H1299 (−p16INK4a/+pRb/deleted-p53). The in vitro clonogenic survival results indicate that Ad/p16 enhanced the radiosensitivity of A549 but not H322 or H1299. Further analysis indicated that the apoptosis induced by combination therapy using Ad/p16 plus irradiation was dependent on the endogenous p53 status of the cancer cells. We performed Western blotting to analyse the p53 protein expression of A549 cells treated with either Ad/p16 or Ad/Luc. Endogenous p53 protein levels were higher in A549 cells transfected with Ad/p16 than in those transfected with Ad/Luc. Furthermore, when wt-p53 protein expression was restored in H1299 using Ad/p53, Ad/p16 stabilized p53 protein expression and radiosensitized the cells. These results suggest that Ad/p16-induced stabilization of p53 protein may play an important role in Ad/p16 mediated radiosensitization by enhancing or restoring apoptosis properties. Thus, Ad/p16 plus radiation in combination may be a useful gene therapy strategy for tumors that have wt-p53 but nonfunctional p16INK4a.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashcroft M and Vousden KH. . 1999 Oncogene 18: 7637–7643.
Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P and Cowan K. . 1998 Oncogene 16: 1–8.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.
Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast Jr RC and Mills GB. . 1998 Int. J. Oncol. 12: 665–669.
Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN and Ronai Z. . 1998 Genes Dev. 12: 2658–2663.
Gallardo D, Drazan KE and McBride WH. . 1996 Cancer Res. 56: 4891–4893.
Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung YK and Israel MA. . 1995 EMBO J. 14: 461–472.
Jin X, Nguyen D, Zhang WW, Kyritsis AP and Roth JA. . 1996 Oncogene 12: 103–110.
Kataoka M, Wiehle S, Spitz F, Schumacher G, Roth JA and Cristiano RJ. . 2000 Oncogene 19: 1589–1595.
Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA and Geradts J. . 1996 Cancer Res. 56: 3415–3420.
Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J. . 1995 Nature 375: 503–506.
McPake CR, Shetty S, Kitchingman GR and Harris LC. . 1999 Cancer Res. 59: 4247–4251.
Miyakoshi J, Kitagawa K, Yamagishi N, Ohtsu S, Day III RS and Takebe H. . 1997 Jpn. J. Cancer Res. 88: 34–38.
Mukhopadhyay T and Roth JA. . 1993 Cancer Res. 53: 4362–4366.
Nevins JR. . 1992 Science 258: 424–429.
Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T and Ueda R. . 1996 J. Clin. Oncol. 14: 497–502.
Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR. . 1994 Exp. Cell. Res. 211: 90–98.
Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ. . 1994 Oncogene 9: 3375–3378.
Sandig V, Brand K, Herwig S, Lukas J, Bartek J and Strauss M. . 1997 Nat. Med. 3: 313–319.
Serrano M, Hannon GJ and Beach D. . 1993 Nature 366: 704–707.
Sherr CJ and Weber JD. . 2000 Curr. Opin. Genet. Dev. 10: 94–99.
Shim J, Park HS, Kim MJ, Park J, Park E, Cho SG, Eom SJ, Lee HW, Joe CO and Choi EJ. . 2000 J. Biol. Chem. 275: 14107–14111.
Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ and Roth JA. . 1996 Clin. Cancer Res. 2: 1665–1671.
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD. . 1989 Science 246: 491–494.
Weinberg RA. . 1995 Cell. 81: 323–330.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. . 1993 Nature 366: 701–704.
Yap DB, Hsieh JK, Chan FS and Lu X. . 1999 Oncogene 18: 7681–7689.
Acknowledgements
This study was supported in part by grants PO1 CA78778, P01 CA06294, and CCSG CA16672 from the National Cancer Institute. The vectors used in this research were the kind gift of Introgen Therapeutics, INC.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawabe, S., Roth, J., Wilson, D. et al. Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 19, 5359–5366 (2000). https://doi.org/10.1038/sj.onc.1203935
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203935
Keywords
This article is cited by
-
Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma
Scientific Reports (2022)
-
CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development
Oncogene (2019)
-
A benzoxazine derivative specifically inhibits cell cycle progression in p53-wild type pulmonary adenocarcinoma cells
Frontiers in Biology (2010)
-
p16 gene transfer increases cell killing with abnormal nucleation after ionising radiation in glioma cells
British Journal of Cancer (2003)
-
Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line
Cancer Chemotherapy and Pharmacology (2003)